The short answer

Cannabis is still a Schedule I controlled substance under federal law. The push to move it to Schedule III began in 2022, produced a formal DEA proposal in May 2024, and then stalled at the administrative hearing stage. No final rule exists. That means federal law has not changed, your state license still carries all the weight, and nothing at the dispensary counter is different today than it was two years ago.

thc schedule classification changes

How the process got here

• October 2022: President Biden pardoned federal simple possession offenses and directed the Attorney General and HHS to review how cannabis is scheduled.
• August 2023: HHS recommended moving cannabis from Schedule I to Schedule III, based on an FDA-led review of the eight statutory factors DEA is supposed to weigh.
• January 2024: The unredacted HHS letter became public, confirming the recommendation and the reasoning behind it.
• May 2024: DEA published a notice of proposed rulemaking in the Federal Register. This was the first formal step, and the one that mattered most.
• July 2024: The public comment window closed with tens of thousands of comments, the large majority in favor.
• Late 2024 into early 2025: DEA scheduled administrative hearings before an administrative law judge. Parties on both sides fought over who got to participate. DEA then cancelled the scheduled hearings and left the docket open.

Formal rulemaking hearings like this one are rare at DEA. The last comparable fight over a scheduling action was decades ago, which is part of why nobody involved seemed sure how the procedure should run.

cannabis rescheduling update news

Why it stalled

Two things happened at once. First, the hearing process bogged down in procedural arguments. The administrative law judge questioned whether HHS had followed the statute properly and whether its recommendation binds DEA at all. It does not, strictly speaking. DEA has to consider the HHS view, and historically it follows it, but it is not obligated to.

Is Marijuana Becoming Legal Federally? What's Moving and What Isn't

Second, the politics changed. A new administration means new DEA leadership and a different set of priorities. Rescheduling is a slow, lawyer-heavy project with no obvious political payoff, and it competes with everything else on the agency's plate. Add in unresolved questions about international treaty obligations and how FDA would regulate cannabis products, and you have a proposal that can sit for a long time without anyone formally killing it.

When Will Cannabis Be Rescheduled? A Guide to the Federal Timeline

What Schedule III would actually change

If the rule is ever finalized, cannabis would sit alongside ketamine, anabolic steroids, and Tylenol with codeine. Concretely, that would:

• Recognize a currently accepted medical use under federal law for the first time.
• Eliminate the 280E tax problem, which currently blocks state-legal operators from taking normal business deductions.
• Loosen research friction and some DEA registration hurdles that come with Schedule I status.
• Shift federal enforcement priorities, though trafficking a Schedule III drug remains a federal crime.

What it would not change

• It does not legalize cannabis federally for adult use. Schedule III is still a controlled substance.
• It does not release anyone from prison or clear records.
• It does not override state law. State-legal markets stay state-legal, and state-illegal states stay illegal.
• It does not fully fix banking. Banks answer to federal money-laundering rules, and rescheduling leaves plenty of risk on the table.
• It does not turn your medical card into a prescription, and it does not put cannabis on pharmacy shelves.

There is also a wrinkle nobody has solved: a Schedule III drug normally requires DEA registration to manufacture, distribute, or dispense. Whether thousands of state-licensed dispensaries could obtain that registration is an open question, and it is one reason some advocates who wanted full descheduling are lukewarm on Schedule III.

What to watch next

• Whether DEA restarts the hearings, issues a final rule, or simply leaves the proposal dormant.
• Who runs DEA, and whether that person treats this as a priority or a landmine.
• Congress. Descheduling bills, banking legislation, and hemp rules could all move ahead of the administrative path, or fall behind it.
• The courts. Any final rule will get challenged, and federal litigation runs on a multi-year clock.

What it means for you

Nothing changes at the counter, and it will not for a while. My read is that this is a multi-year process that has survived longer than most people expected and moved slower than advocates hoped. If something does land, the visible effects for customers would come through business economics: better access to capital, more normal tax treatment, and over time a sturdier supply chain. Those are real wins, but they are not the same as legalization, and anyone telling you otherwise is selling something.